WP
NMRA icon

Woodline Partners’s Neumora Therapeutics NMRA Stock Holding History

Woodline Partners’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,957
Closed -$29.2K – 1111
2026
Q1 		$29.2K Hold
14,957
– – ﹤0.01% 1022
2025
Q4 		$26.8K Hold
14,957
– – ﹤0.01% 1010
2025
Q3 		$27.2K Hold
14,957
– – ﹤0.01% 869
2025
Q2 		$11K Hold
14,957
– – ﹤0.01% 911
2025
Q1 		$15K Sell
14,957
-295,497
-95% -$506K ﹤0.01% 890
2024
Q4 		$3.29M Buy
310,454
+2,896
+0.9% +$34.7K 0.02% 569
2024
Q3 		$4.06M Buy
307,558
+143,398
+87% +$1.67M 0.03% 412
2024
Q2 		$1.61M Buy
+164,160
New +$1.7M 0.02% 436

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Woodline Partners's NMRA Position: Q2 2026 in Review

Woodline Partners sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 14,957 shares — an estimated $29.2K sold.

Woodline Partners first reported a position in NMRA in Q2 2024 and held it in 8 quarters. The position peaked at $4.06M in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Woodline Partners reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 14,957 Neumora Therapeutics shares in Q2 2026, an estimated $29.2K.
  • Woodline Partners first reported a position in Neumora Therapeutics in Q2 2024 and held it in 8 quarters.
  • Woodline Partners's Neumora Therapeutics position peaked at $4.06M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.